Fast Troponin as a Biomarker to Assess Exercise-induced Muscle Damage in Muscle Diseases

The purpose of the study is to explore the biomarker Fast Troponins response to exercise in patients with Becker muscular dystrophy, Limb-girdle muscular dystrophy and McArdle disease

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Becker Muscular Dystrophy Carbohydrate Metabolism, Inborn Errors Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Genetic Diseases, X-Linked Glycogen Storage Disease Glycogen Storage Disease Type V Limb-Girdle Muscular Dystrophy Type 2 Limb-girdle muscular dystrophy type 2A McArdle Disease Metabolic Diseases Metabolism, Inborn Errors Muscular Diseases Muscular Disorders, Atrophic Muscular Dystrophies Muscular Dystrophy, Duchenne Musculoskeletal Diseases Nervous System Diseases Neuromuscular Diseases Nutritional and Metabolic Diseases

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Neuromuscular Research Unit, 3342

Copenhagen, DK-2100, Denmark

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

The ability to cycle
No concurrent medical condition that could interfere with interpretation of the results
Molecular diagnosis of the specific condition in specified patient groups or healthy control
No active muscle injury on the test day (caused by recent exercise, seizures, trauma, etc.)

Exclusion criteria

Competing conditions at risk of compromising the results of the study
Cardiac or pulmonary disease contraindicating peak exercise testing or strenuous exercise
Veins that are too difficult to puncture for blood sampling, evaluated by the investigator
Severe muscle weakness, that prevents the subject completing the exercise test, evaluated by the investigator

Treatment and study plan

Primary outcomes

Change in biomarkers

Time frame: 24 hours

Change in Fast and slow Troponin I after muscle damage

Sponsors and collaborators

Lead sponsor

Mads Peter Godtfeldt Stemmerik

Other

Collaborators

Edgewise Therapeutics, Inc.

Registry information

Important dates

Study start: 2020
Primary completion: 2021
Study completion: 2021
First posted: Apr 16, 2020
Registry last updated: Oct 27, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed